Flavonoid compounds as reversal agents of the P-glycoprotein-mediated multidrug resistance: biology, chemistry and pharmacology

Phytochemistry Reviews

Volumn 14, Issue 2, 2015, Pages 233-272

  Ferreira, Ana ^a,b   Pousinho, Sarah ^a   Fortuna, Ana ^b,c   Falcão, Amílcar ^b,c   Alves, Gilberto ^a,b  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Drug efflux; Flavonoids; Multidrug resistance; P glycoprotein inhibition

Indexed keywords

EID: 84939874562     PISSN: 15687767     EISSN: 1572980X     Source Type: Journal    
DOI: 10.1007/s11101-014-9358-0     Document Type: Review

References (207)

1. Ali H-A, Chowdhury AKA, Rahman AKM et al (2008) Pachypodol, a flavonol from the leaves of Calycopteris floribunda, inhibits the growth of CaCo-2 colon cancer cell line in vitro. Phytother Res 22:1684–1687
2. Alonso-Castro AJ, Ortiz-Sánchez E, García-Regalado A et al (2013) Kaempferitrin induces apoptosis via intrinsic pathway in HeLa cells and exerts antitumor effects. J Ethnopharmacol 145:476–489
3. Alvarez AI, Real R, Pérez M et al (2010) Modulation of the activity of ABC transporters (P-Glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci 99:598–617
4. Amin ML (2013) P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7:27–34
5. An G, Morris ME (2010) Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo. Biopharm Drug Dispos 31:340–350
6. Aszalos A (2008) Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs. Curr Drug Metab 9:1010–1018
7. Badhan R, Penny J (2006) In silico modelling of the interaction of flavonoids with human P-glycoprotein nucleotide-binding domain. Eur J Med Chem 41:285–295
8. Balayssac D, Authier N, Cayre A, Coudore F (2005) Does inhibition of P-glycoprotein lead to drug–drug interactions? Toxicol Lett 156:319–329
9. Bansal T, Awasthi A, Jaggi M et al (2008) Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein. Life Sci 83:250–259
10. Bansal T, Jaggi M, Khar RK, Talegaonkar S (2009) Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12:46–78
11. Barron D, Di Pietro A, Dumontet C, Mcintosh DB (2003) Isoprenoid flavonoids are new leads in the modulation of chemoresistance. Phytochem Rev 1:325–332
12. Bellamy WT (1996) P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 36:161–183
13. Bois F, Beney C, Boumendjel A et al (1998) Halogenated chalcones with high-affinity binding to P-glycoprotein: potential modulators of multidrug resistance. J Med Chem 41:4161–4164
14. Bois F, Boumendjel A, Mariotte AM et al (1999) Synthesis and biological activity of 4-alkoxy chalcones: potential hydrophobic modulators of P-glycoprotein-mediated multidrug resistance. Bioorg Med Chem 7:2691–2695
15. Borska S, Sopel M, Chmielewska M et al (2010) Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules 15:857–870
16. Boumendjel A, Di Pietro A, Dumontet C, Barron D (2002) Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev 22:512–529
17. Brand W, Schutte ME, Williamson G et al (2006) Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed Pharmacother 60:508–519
18. Brandt C, Bethmann K, Gastens AM, Löscher W (2006) The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 24:202–211
19. Breier A, Gibalova L, Seres M et al (2013) New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem 13:159–170
20. Buer CS, Imin N, Djordjevic MA (2010) Flavonoids: new roles for old molecules. J Integr Plant Biol 52:98–111
21. Cassidy CE, Setzer WN (2010) Cancer-relevant biochemical targets of cytotoxic Lonchocarpus flavonoids: a molecular docking analysis. J Mol Model 16:311–326
22. Castro AF, Altenberg GA (1997) Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem Pharmacol 53:89–93
23. Castro WVDE, Mertens-Talcott S, Derendorf H (2007) Grapefruit juice-drug interactions: grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci 96:2808–2817
24. Chan LMS, Lowes S, Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25–51
25. Chan K-F, Zhao Y, Chow TWS et al (2009) Flavonoid dimers as bivalent modulators for p-glycoprotein-based multidrug resistance: structure-activity relationships. ChemMedChem 4:594–614
26. Chang X (2007) A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1. Cancer Metastasis Rev 26:15–37
27. Chang C, Bahadduri PM, Polli JE et al (2006) Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 34:1976–1984
28. Chen C, Zhou J, Ji C (2010) Quercetin: a potential drug to reverse multidrug resistance. Life Sci 87:333–338
29. Chieli E, Romiti N, Rodeiro I, Garrido G (2009) In vitro effects of Mangifera indica and polyphenols derived on ABCB1/P-glycoprotein activity. Food Chem Toxicol 47:2703–2710
30. Cho Y-A, Choi D-H, Choi J-S (2009) Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. J Pharm Pharmacol 61:825–829
31. Cho Y-A, Choi J-S, Burm J-P (2011) Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein. Pharmacol Rep 63:1066–1073
32. Choi J-S, Burm JP (2006) Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits. Arch Pharm Res 29:333–338
33. Choi J-S, Han H-K (2005) Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats. Pharmacol Res 52:386–391
34. Choi J-S, Kang KW (2008) Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin. Arch Pharm Res 31:1631–1636
35. Choi J-S, Li X (2005) Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits. Int J Pharm 297:1–8
36. Choi J-S, Choi H-K, Shin S-C (2004a) Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int J Pharm 275:165–170
37. Choi J-S, Jo B-W, Kim Y-C (2004b) Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 57:313–318
38. Choi B-C, Choi J-S, Han H-K (2006) Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Int J Pharm 323:81–85
39. Choi D-H, Li C, Choi J-S (2010) Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. J Pharm Pharmacol 62:908–914
40. Choi J-S, Piao Y-J, Kang KW (2011a) Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 34:607–613
41. Choi S-J, Shin S-C, Choi J-S (2011b) Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin. Arch Pharm Res 34:309–315
42. Chokchaisiri R, Suaisom C, Sriphota S et al (2009) Bioactive flavonoids of the flowers of Butea monosperma. Chem Pharm Bull (Tokyo) 57:428–432
43. Chung SY, Sung MK, Kim NH et al (2005) Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res 28:823–828
44. Chung SY, Jang DS, Han A et al (2007) Modulation of P-glycoprotein-mediated resistance by kaempferol derivatives isolated from Zingiber zerumbet. Phytother Res 21:565–569
45. Coley HM (2010) Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol 596:341–358
46. Comte G, Daskiewicz JB, Bayet C et al (2001) C-Isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance. J Med Chem 44:763–768
47. Conseil G, Baubichon-Cortay H, Dayan G et al (1998) Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 95:9831–9836
48. Cook N, Samman S (1996) Flavonoids: chemistry, metabolism, cardioprotective effects, and dietary sources. J Nutr Biochem 7:66–76
49. Corea G, Di Pietro A, Dumontet C et al (2009) Jatrophane diterpenes from Euphorbia spp. as modulators of multidrug resistance in cancer therapy. Phytochem Rev 8:431–447
50. Crozier A, Jaganath IB, Clifford MN (2009) Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 26:1001–1043
51. Dantzig AH, de Alwis DP, Burgess M (2003) Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 55:133–150
52. De Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V (2008) Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats. J Agric Food Chem 56:4840–4845
53. De Wet H, McIntosh DB, Conseil G et al (2001) Sequence requirements of the ATP-binding site within the C-terminal nucleotide-binding domain of mouse P-glycoprotein: structure-activity relationships for flavonoid binding. Biochemistry 40:10382–10391
54. Deeley RG, Westlake C, Cole SPC (2006) Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86:849–899
55. Deferme S, Augustijns P (2003) The effect of food components on the absorption of P-gp substrates: a review. J Pharm Pharmacol 55:153–162
56. Del Amo EM, Heikkinen AT, Mönkkönen J (2009) In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption. Eur J Pharm Sci 36:200–211
57. Di Pietro A, Conseil G, Pérez-victoria JM et al (2002) Cellular and molecular life sciences modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci 59:307–322
58. Dinis-Oliveira RJ, Remião F, Duarte J et al (2006) P-glycoprotein induction: an antidotal pathway for paraquat-induced lung toxicity. Free Radic Biol Med 41:1213–1224
59. Doran A, Obach RS, Smith BJ et al (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165–174
60. Du G-J, Zhang Z, Wen X-D et al (2012) Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients 4:1679–1691
61. Fang S-H, Hou Y-C, Chao P-DL (2005) Pharmacokinetic and pharmacodynamic interactions of morin and cyclosporin. Toxicol Appl Pharmacol 205:65–70
62. Fernández SP, Wasowski C, Paladini AC, Marder M (2005) Synergistic interaction between hesperidin, a natural flavonoid, and diazepam. Eur J Pharmacol 512:189–198
63. Fortuna A, Alves G, Falcão A (2011) In vitro and in vivo relevance of the P-glycoprotein probe substrates in drug discovery and development: focus on rhodamine 123, digoxin and talinolol. J Bioequiv Availab 01:1–23
64. Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25:423–429
65. Gazák R, Walterová D, Kren V (2007) Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 14:315–338
66. Giacomini KM, Huang S-M, Tweedie DJ et al (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236
67. Girardin F (2006) Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin Neurosci 8:311–321
68. Go WJ, Ryu JH, Qiang F, Han H-K (2009) Evaluation of the flavonoid oroxylin A as an inhibitor of P-glycoprotein-mediated cellular efflux. J Nat Prod 72:1616–1619
69. Guidance for Industry (2006) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. U.S. Department of Health and Human Services, FDA, CDER, CBER
70. Hadjeri M, Barbier M, Ronot X et al (2003) Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues. J Med Chem 46:2125–2131
71. Harborne JB (1962) Plant polyphenols. 5: occurrence of azalein and related pigments in flowers of Plumbago and Rhododendron species. Arch Biochem Biophys 96:171–178
72. Hasegawa M, Shirato T (2002) Two new flavonoid glycosides from the leaves of Phellodendron amurense Ruprecht. J Am Chem Soc 75:5507–5511
73. Hendrich AB (2006) Flavonoid-membrane interactions: possible consequences for biological effects of some polyphenolic compounds. Acta Pharmacol Sin 27:27–40
74. Hennessy M, Spiers JP (2007) A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res 55:1–15
75. Horowitz RM, Gentili B (1960) Flavonoids of the Ponderosa lemon. Nature 185:319
76. Hsiu S-L, Hou Y-C, Wang Y-H et al (2002) Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci 72:227–235
77. Huisman MT, Smit JW, Wiltshire HR et al (2003) Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir. J Pharmacol Exp Ther 304:596–602
78. Ikegawa T, Ushigome F, Koyabu N, Morimoto S (2000) Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett 160:21–28
79. Jäger AK, Saaby L (2011) Flavonoids and the CNS. Molecules 16:1471–1485
80. Jeong J-M, Choi C-H (2007) Enhancement of paclitacel transport and cytotoxicity by 7,3’,4’-trimethoxyflavone, a P-glycoprotein inhibitor. J Pharm Pharm Sci 10:547–553
81. Jodoin J, Demeule M, Beliveau R (2002) Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 1542:149–159
82. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162
83. Katiyar SK, Meleth S, Sharma SD (2008) Silymarin, a flavonoid from milk thistle (Silybum marianum L.), inhibits UV-induced oxidative stress through targeting infiltrating CD11b+ cells in mouse skin. Photochem Photobiol 84:266–271
84. Kellenberger E, Kuhn I, Schuber F, Muller-Steffner H (2011) Flavonoids as inhibitors of human CD38. Bioorg Med Chem Lett 21:3939–3942
85. Kemper EM, van Zandbergen AE, Cleypool C et al (2003) Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res 9:2849–2855
86. Keung WM, Vallee BL (1993) Daidzin: a potent, selective inhibitor of human mitochondrial aldehyde dehydrogenase. Proc Natl Acad Sci USA 90:1247–1251
87. Khan IA, Avery MA, Burandt CL et al (2000) Antigiardial activity of isoflavones from Dalbergia frutescens bark. J Nat Prod 63:1414–1416
88. Khantamat O, Chaiwangyen W, Porn-ngarm L (2004) Screening of flavonoids for their potential inhibitory effect on p-glycoprotein activity in human cervical carcinoma KB cells. Chiang Mai Med Bull 43:45–56
89. Kim D-H, Na H-K, Oh TY et al (2004) Eupatilin, a pharmacologically active flavone derived from Artemisia plants, induces cell cycle arrest in ras-transformed human mammary epithelial cells. Biochem Pharmacol 68:1081–1087
90. Kim K-A, Park P-W, Park J-Y (2009) Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur J Clin Pharmacol 65:609–614
91. Kim YH, Lee YS, Choi EM (2010) Chrysoeriol isolated from Eurya cilliata leaves protects MC3T3-E1 cells against hydrogen peroxide-induced inhibition of osteoblastic differentiation. J Appl Toxicol 30:666–673
92. Kitagawa S (2006) Inhibitory effects of polyphenols on p-glycoprotein-mediated transport. Biol Pharm Bull 29:1–6
93. Kitagawa S, Nabekura T, Kamiyama S (2004) Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J Pharm Pharmacol 56:1001–1005
94. Kitagawa S, Nabekura T, Takahashi T et al (2005) Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull 28:2274–2278
95. Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265–283
96. Kubota H, Ishihara H, Langmann T et al (2006) Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res 68:213–228
97. Kumar G, Karthik L, Rao KVB (2013) Phytochemical composition and in vitro antioxidant activity of aqueous extract of Aerva lanata (L.) Juss. ex Schult. Stem (Amaranthaceae). Asian Pac J Trop Med 6:180–187
98. Kwan P, Brodie MJ (2005) Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 46:224–235
99. Lam IK, Alex D, Wang Y-H et al (2012) In vitro and in vivo structure and activity relationship analysis of polymethoxylated flavonoids: identifying sinensetin as a novel antiangiogenesis agent. Mol Nutr Food Res 56:945–956
100. Lazarowski A, Czornyj L, Lubienieki F et al (2007) ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 48(Suppl 5):140–149
101. Lee C-K, Choi J-S (2010) Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Pharmacology 85:350–356
102. Ley JP, Krammer G, Reinders G et al (2005) Evaluation of bitter masking flavanones from Herba Santa (Eriodictyon californicum (H. and A.) Torr., Hydrophyllaceae). J Agric Food Chem 53:6061–6066
103. Li X, Choi J-S (2007) Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. Int J Pharm 337:188–193
104. Li C, Choi JS (2008) Effects of epigallocatechin gallate on the bioavailability and pharmacokinetics of diltiazem in rats. Pharmazie 63:815–818
105. Li X, Choi J-S (2009) Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats. Anticancer Res 29:1411–1415
106. Li X, Yun J-K, Choi J-S (2007) Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos 28:151–156
107. Li C, Li X, Choi J-S (2009) Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats. Arch Pharm Res 32:133–138
108. Li C, Kim M, Choi H, Choi J (2011) Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein. Arch Pharm Res 34:1965–1972
109. Lim S-C, Choi J-S (2006) Effects of naringin on the pharmacokinetics of intravenous paclitaxel in rats. Biopharm Drug Dispos 27:443–447
110. Lin JH (2003) Drug–drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 55:53–81
111. Lin JH, Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42:59–98
112. Ling V (1997) Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40(Suppl):S3–S8
113. Linnet K, Ejsing TB (2008) A review on the impact of P-glycoprotein on the penetration of drugs into the brain: focus on psychotropic drugs. Eur Neuropsychopharmacol 18:157–169
114. Lohner K, Schnäbele K, Daniel H et al (2007) Flavonoids alter P-gp expression in intestinal epithelial cells in vitro and in vivo. Mol Nutr Food Res 51:293–300
115. Löscher W, Potschka H (2002a) Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 301:7–14
116. Löscher W, Potschka H (2002b) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22–76
117. Löscher W, Potschka H (2005) Blood-brain barrier active efflux transporters: aTP-binding cassette gene family. NeuroRx 2:86–98
118. Makino T, Kanemaru M, Okuyama S et al (2013) Anti-allergic effects of enzymatically modified isoquercitrin (α-oligoglucosyl quercetin 3-O-glucoside), quercetin 3-O-glucoside, α-oligoglucosyl rutin, and quercetin, when administered orally to mice. J Nat Med 67:881–886
119. Marquez B, Van Bambeke F (2011) ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug–drug interactions. Curr Drug Targets 12:600–620
120. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM (2001) Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 21:778–796
121. Matsui T, Ito C, Itoigawa M et al (2009) Effect of natsudaidain isolated from Citrus plants on TNF-alpha and cyclooxygenase-2 expression in RBL-2H3 cells. J Pharm Pharmacol 61:109–114
122. Mertens-Talcott SU, De Castro WV, Manthey JA et al (2007) Polymethoxylated flavones and other phenolic derivates from citrus in their inhibitory effects on P-glycoprotein-mediated transport of talinolol in Caco-2 cells. J Agric Food Chem 55:2563–2568
123. Miller DS, Bauer B, Hart AMS (2009) Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve CNS pharmacotherapy. Pharmacol Rev 60:196–209
124. Mitsunaga Y, Takanaga H, Matsuo H et al (2000) Effect of bioflavonoids on vincristine transport across blood–brain barrier. Eur J Pharmacol 395:193–201
125. Miyake Y, Mochizuki M, Okada M et al (2007) Isolation of antioxidative phenolic glucosides from lemon juice and their suppressive effect on the expression of blood adhesion molecules. Biosci Biotechnol Biochem 71:1911–1919
126. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425–461
127. Moon YJ, Wang X, Morris ME (2006) Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol Vitr 20:187–210
128. Moreno Escobosa MC, Cruz Granados S, Moya Quesada MC (2012) Erythema and hand edema due to flavoxate. J Investig Allergol Clin Immunol 22:390–391
129. Morris ME, Zhang S (2006) Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 78:2116–2130
130. Ofer M, Wolffram S, Koggel A et al (2005) Modulation of drug transport by selected flavonoids: involvement of P-gp and OCT? Eur J Pharm Sci 25:263–271
131. Ogawa Y, Oku H, Iwaoka E et al (2006) Allergy-preventive phenolic glycosides from Populus sieboldii. J Nat Prod 69:1215–1217
132. Palmeira A, Rodrigues F, Sousa E et al (2011) New uses for old drugs: pharmacophore-based screening for the discovery of P-glycoprotein inhibitors. Chem Biol Drug Des 78:57–72
133. Park JH, Park JH, Hur HJ et al (2012) Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. Eur J Pharm Sci 45:296–301
134. Patanasethanont D, Nagai J, Yumoto R et al (2007) Effects of Kaempferia Parviflora extracts and their flavone constituents on P-glycoprotein function. J Pharm Sci 96:223–233
135. Pathak SM, Udupa N (2010) Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin. Biopharm Drug Dispos 31:202–214
136. Peng SX, Ritchie DM, Cousineau M et al (2006) Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J Pharm Sci 95:1984–1993
137. Pérez-Tomás R (2006) Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13:1859–1876
138. Piao Y-J, Choi J-S (2008a) Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats. J Pharm Pharmacol 60:625–629
139. Piao Y-J, Choi J-S (2008b) Enhanced bioavailability of verapamil after oral administration with hesperidin in rats. Arch Pharm Res 31:518–522
140. Piao Y-J, Shin S-C, Choi J-S (2008) Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats. Biopharm Drug Dispos 29:245–249
141. Potschka H (2012) Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport. Adv Drug Deliv Rev 64:943–952
142. PubChem Coumpound Database PubChem Coumpound Database. http://www.ncbi.nlm.nih.gov/pccompound/
143. Raj (2001) Bioflavonoids classification, pharmacological, biochemical effects and therapeutic potential. Indian J Pharmacol 33:2
144. Rakwal R, Agrawal G, Yonekura M, Kodama O (2000) Naringenin 7-O-methyltransferase involved in the biosynthesis of the flavanone phytoalexin sakuranetin from rice (Oryza sativa L.). Plant Sci 155:213–221
145. Ramakrishnan P (2003) The role of P-glycoprotein in the blood–brain barrier. Einstein J Biol Med 19:160–165
146. Rao BN, Srinivas M, Kumar YS, Rao YM (2007) Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers. Drug Metab Drug Interact 22:175–185
147. Rao YK, Lee M-J, Chen K et al (2011) Insulin-mimetic action of rhoifolin and cosmosiin isolated from Citrus grandis (L.) Osbeck leaves: enhanced adiponectin secretion and insulin receptor phosphorylation in 3T3-L1 Cells. Evid Based Complement Alternat Med 2011:624375
148. Raub TJ (2006) P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm 3:3–25
149. Romano B, Pagano E, Montanaro V et al (2013) Novel Insights into the pharmacology of flavonoids. Phytother Res 27:1588–1596
150. Romiti N, Tramonti G, Donati A, Chieli E (2004) Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. Life Sci 76:293–302
151. Ross JA, Kasum CM (2002) Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 22:19–34
152. Sacco S, Maffei M (1997) The effect of isosakuranetin (5,7-dihydroxy 4′-methoxy flavanone) on potassium uptake in wheat root segments. Phytochemistry 46:245–248
153. Sauna ZE, Smith MM, Marianna M, Kerr KM (2001) The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 33:481–491
154. Scambia G, Ranelletti FO, Panici PB et al (1994) Quercetin potentiates the effect of Adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34:459–464
155. Schinkel A (1999) P-Glycoprotein, a gatekeeper in the blood–brain barrier. Adv Drug Deliv Rev 36:179–194
156. Schinkel AH, Jonker JW (2012) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3–29
157. Seegers U, Potschka H, Löscher W (2002) Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. Eur J Pharmacol 451:149–155
158. Shajib MTI, Pedersen HA, Mortensen AG et al (2012) Phytotoxic effect, uptake, and transformation of biochanin A in selected weed species. J Agric Food Chem 60:10715–10722
159. Sheu M-T, Liou Y-B, Kao Y-H et al (2010) A quantitative structure-activity relationship for the modulation effects of flavonoids on p-glycoprotein-mediated transport. Chem Pharm Bull (Tokyo) 58:1187–1194
160. Shin S-C, Choi J-S, Li X (2006) Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm 313:144–149
161. Shin S-C, Piao Y-J, Choi J-S (2008) Effects of morin on the bioavailability of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. In Vivo (Brooklyn) 22:391–395
162. Shin SC, Li C, Choi JS (2009) Effects of baicalein, an antioxidant, on the bioavailability of doxorubicin in rats: possible role of P-glycoprotein inhibition by baicalein. Pharmazie 64:579–583
163. Shohai T, Shafique M, Dhanya N, Divakar MC (2011) Importance of flavonoides in therapeutics. Hygeia J D Med 3:1–18
164. Singh SP, Wahajuddin Raju KSR et al (2012) Reduced bioavailability of tamoxifen and its metabolite 4-hydroxytamoxifen after oral administration with biochanin A (an isoflavone) in rats. Phytother Res 26:303–307
165. Spencer JPE (2007) The interactions of flavonoids within neuronal signalling pathways. Genes Nutr 2:257–273
166. Stouch TR, Gudmundsson O (2002) Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev 54:315–328
167. Sugimoto H, Hirabayashi H, Kimura Y et al (2011) Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood–brain barrier in rats. Drug Metab Dispos 39:8–14
168. Sun H, Dai H, Shaik N, Elmquist WF (2003) Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55:83–105
169. Sun J, He Z-G, Cheng G et al (2004) Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 10:5–14
170. Takanaga H, Ohnishi A, Matsuo H, Sawada Y (1998) Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 21:1062–1066
171. Takanaga H, Ohnishi A, Yamada S et al (2000) Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cythocrome P450 3A4. J Pharmacol Exp Ther 293:230–236
172. Tandon VR, Kapoor B, Bano G et al (2006) P-glycoprotein: pharmacological relevance relevance. Indian J Pharmacol 38:13–24
173. Tapas AR, Sakarkar DM, Kakde RB (2008) Flavonoids as nutraceuticals: a Review. Trop J Pharm Res 7:1089–1099
174. Thilakarathna SH, Rupasinghe HPV (2013) Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients 5:3367–3387
175. Thomas H, Coley HM (2013) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159–165
176. Toh JY, Tan VMH, Lim PCY et al (2013) Flavonoids from fruit and vegetables: a focus on cardiovascular risk factors. Curr Atheroscler Rep 15:368
177. Toki K, Saito N, Irie Y et al (2008) 7-O-Methylated anthocyanidin glycosides from Catharanthus roseus. Phytochemistry 69:1215–1219
178. Tran VH, Marks D, Duke RK et al (2011) Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions. Nutr Cancer 63:435–443
179. Trompier D, Baubichon-Cortay H, Chang X-B et al (2003) Multiple flavonoid-binding sites within multidrug resistance protein MRP1. Cell Mol Life Sci 60:2164–2177
180. Tsuji PA, Stephenson KK, Wade KL et al (2013) Structure-activity analysis of flavonoids: direct and indirect antioxidant, and antiinflammatory potencies and toxicities. Nutr Cancer 65:1014–1025
181. Udaya Kumar N, Sailendra M, Peddanna K et al (2011) Virtual screening of flavonoids as inhibitory agents of p-glycoprotein. IJABPT 2:130–140
182. Van der Kolk DM, de Vries EG, van Putten WJ et al (2000) P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 6:3205–3214
183. Varma M (2003) P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 48:347–359
184. Vauzour D, Vafeiadou K, Rodriguez-Mateos A et al (2008) The neuroprotective potential of flavonoids: a multiplicity of effects. Genes Nutr 3:115–126
185. Volk H, Burkhardt K, Potschka H et al (2004) Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 123:751–759
186. Wagner H, Aurnhammer G, Hörhammer L et al (1969) Synthesis of poncirin, an isosakuranetin-7-beta-neohesperidoside from Poncirus trifoliata Raf. Chem Ber 102:785–791
187. Wang EJ, Casciano CN, Clement RP, Johnson WW (2001) Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm Res 18:432–438
188. Wang E, Barecki-Roach M, Johnson WW (2002) Elevation of P-glycoprotein function by a catechin in green tea. Biochem Biophys Res Commun 297:412–418
189. Wang Y-H, Chao P-DL, Hsiu S-L et al (2004) Lethal quercetin-digoxin interaction in pigs. Life Sci 74:1191–1197
190. Wang Y-H, Li Y, Yang S-L, Yang L (2005) An in silico approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network. J Comput Aided Mol Des 19:137–147
191. Wang H, Zhao X, Wang Y, Yin S (2007) Potential toxicities of flavonoids. Wei Sheng Yan Jiu 36:640–642
192. Wasowski C, Marder M (2012) Flavonoids as GABA A receptor ligands: the whole story? J Exp Pharmacol 4:9–24
193. Wesołowska O (2011) Interaction of phenothiazines, stilbenes and flavonoids with multidrug resistance-associated transporters, P-glycoprotein and MRP1. Acta Biochim Pol 58:433–448
194. Wesołowska O, Hendrich AB, Łaniapietrzak B et al (2009) Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids. Cell Mol Biol Lett 14:199–221
195. Yang K, Wu J, Li X (2008) Recent advances in the research of P-glycoprotein inhibitors. Biosci Trends 2:137–146
196. Yang SH, Lee JH, Lee DY et al (2011) Effects of morin on the pharmacokinetics of docetaxel in rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors. Arch Pharm Res 34:1729–1734
197. Yang J, Qian D, Guo J et al (2013) Identification of the major metabolites of hyperoside produced by the human intestinal bacteria using ultra performance liquid chromatography/quadrupole-time-of-flight mass spectrometry. J Ethnopharmacol 147:174–179
198. Yeum C-H, Choi J-S (2006) Effect of naringin pretreatment on bioavailability of verapamil in rabbits. Arch Pharm Res 29:102–107
199. Yoo HH, Lee M, Chung HJ et al (2007) Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. J Agric Food Chem 55:7620–7625
200. Zhang S, Morris ME (2003a) Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-Glycoprotein-mediated transport. J Pharmacol Exp Ther 304:1258–1267
201. Zhang S, Morris ME (2003b) Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 20:1184–1191
202. Zhang L, Strong JM, Qiu W et al (2006) Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 3:62–69
203. Zhang J, Yang G, Lin R, Hu Z (2011) Determination of paeoniflorin, calycosin-7-O-β-D-glucoside, ononin, calycosin and formononetin in rat plasma after oral administration of Buyang Huanwu decoction for their pharmacokinetic study by liquid chromatography-mass spectrometry. Biomed Chromatogr 25:450–457
204. Zhang C, Kwan P, Zuo Z, Baum L (2012) The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev 64:930–942
205. Zhou G-X, Lu C-L, Wang H-S, Yao X-S (2009) An acetyl flavonol from Nervilia fordii (Hance) Schltr. J Asian Nat Prod Res 11:498–502
206. Zhu L, Zhao L, Wang H et al (2013) Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest. Toxicol Lett 219:107–115
207. Zou P, Xing L, Tang Q et al (2012) Comparative evaluation of the teratogenicity of genistein and genistin using rat whole embryo culture and limbud micromass culture methods. Food Chem Toxicol 50:2831–2836